Literature DB >> 29795357

Pharmacological and functional comparisons of α6/α3β2β3-nAChRs and α4β2-nAChRs heterologously expressed in the human epithelial SH-EP1 cell line.

De-Jie Chen1,2, Fen-Fei Gao2,3, Xiao-Kuang Ma2,3, Gang-Gang Shi3, Yuan-Bing Huang1,2, Quang-Xi Su1, Sterling Sudweeks4, Ming Gao2, Turner Dharshaun2, Jason Brek Eaton2, Yong-Chang Chang2, J Michael Mcintosh5,6, Ronald J Lukas2, Paul Whiteaker2, Scott C Steffensen7, Jie Wu8,9,10.   

Abstract

Neuronal nicotinic acetylcholine receptors containing α6 subunits (α6*-nAChRs) show highly restricted distribution in midbrain neurons associated with pleasure, reward, and mood control, suggesting an important impact of α6*-nAChRs in modulating mesolimbic functions. However, the function and pharmacology of α6*-nAChRs remain poorly understood because of the lack of selective agonists for α6*-nAChRs and the challenging heterologous expression of functional α6*-nAChRs in mammalian cell lines. In particular, the α6 subunit is commonly co-expressed with α4*-nAChRs in the midbrain, which masks α6*-nAChR (without α4) function and pharmacology. In this study, we systematically profiled the pharmacology and function of α6*-nAChRs and compared these properties with those of α4β2 nAChRs expressed in the same cell line. Heterologously expressed human α6/α3 chimeric subunits (α6 N-terminal domain joined with α3 trans-membrane domains and intracellular loops) with β2 and β3 subunits in the human SH-EP1 cell line (α6*-nAChRs) were used. Patch-clamp whole-cell recordings were performed to measure these receptor-mediated currents. Functionally, the heterologously expressed α6*-nAChRs exhibited excellent function and showed distinct nicotine-induced current responses, such as kinetics, inward rectification and recovery from desensitization, compared with α4β2-nAChRs. Pharmacologically, α6*-nAChR was highly sensitive to the α6 subunit-selective antagonist α-conotoxin MII but had lower sensitivity to mecamylamine and dihydro-β-erythroidine. Nicotine and acetylcholine were found to be full agonists for α6*-nAChRs, whereas epibatidine and cytisine were determined to be partial agonists. Heterologously expressed α6*-nAChRs exhibited pharmacology and function distinct from those of α4β2-nAChRs, suggesting that α6*-nAChRs may mediate different cholinergic signals. Our α6*-nAChR expression system can be used as an excellent cell model for future investigations of α6*-nAChR function and pharmacology.

Entities:  

Keywords:  SH-EP1 cells; acetylcholine; nicotine; nicotinic acetylcholine receptor; patch-clamp

Mesh:

Substances:

Year:  2018        PMID: 29795357      PMCID: PMC6289390          DOI: 10.1038/aps.2017.209

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  36 in total

1.  Incorporation of the beta3 subunit has a dominant-negative effect on the function of recombinant central-type neuronal nicotinic receptors.

Authors:  Steven Broadbent; Paul J Groot-Kormelink; Paraskevi A Krashia; Patricia C Harkness; Neil S Millar; Marco Beato; Lucia G Sivilotti
Journal:  Mol Pharmacol       Date:  2006-07-05       Impact factor: 4.436

2.  A pilot controlled trial of transdermal nicotine in the treatment of attention deficit hyperactivity disorder.

Authors:  R Douglas Shytle; Archie A Silver; Berney J Wilkinson; Paul R Sanberg
Journal:  World J Biol Psychiatry       Date:  2002-07       Impact factor: 4.132

3.  Pharmacological characterisation of α6β4⁎ nicotinic acetylcholine receptors assembled from three chimeric α6/α3 subunits in tsA201 cells.

Authors:  Anne B Jensen; Kirsten Hoestgaard-Jensen; Anders A Jensen
Journal:  Eur J Pharmacol       Date:  2014-06-18       Impact factor: 4.432

4.  Human alpha6 AChR subtypes: subunit composition, assembly, and pharmacological responses.

Authors:  A Kuryatov; F Olale; J Cooper; C Choi; J Lindstrom
Journal:  Neuropharmacology       Date:  2000-10       Impact factor: 5.250

5.  Stable expression and functional characterization of a human nicotinic acetylcholine receptor with α6β2 properties: discovery of selective antagonists.

Authors:  Anna Maria Capelli; Laura Castelletti; Yu Hua Chen; Harjeet Van der Keyl; Luca Pucci; Beatrice Oliosi; Cristian Salvagno; Barbara Bertani; Cecilia Gotti; Andrew Powell; Manolo Mugnaini
Journal:  Br J Pharmacol       Date:  2011-05       Impact factor: 8.739

6.  Menthol Alone Upregulates Midbrain nAChRs, Alters nAChR Subtype Stoichiometry, Alters Dopamine Neuron Firing Frequency, and Prevents Nicotine Reward.

Authors:  Brandon J Henderson; Teagan R Wall; Beverley M Henley; Charlene H Kim; Weston A Nichols; Ruin Moaddel; Cheng Xiao; Henry A Lester
Journal:  J Neurosci       Date:  2016-03-09       Impact factor: 6.167

7.  Cholinergic modulation of locomotion and striatal dopamine release is mediated by alpha6alpha4* nicotinic acetylcholine receptors.

Authors:  Ryan M Drenan; Sharon R Grady; Andrew D Steele; Sheri McKinney; Natalie E Patzlaff; J Michael McIntosh; Michael J Marks; Julie M Miwa; Henry A Lester
Journal:  J Neurosci       Date:  2010-07-21       Impact factor: 6.167

8.  A novel T-type current underlies prolonged Ca(2+)-dependent burst firing in GABAergic neurons of rat thalamic reticular nucleus.

Authors:  J R Huguenard; D A Prince
Journal:  J Neurosci       Date:  1992-10       Impact factor: 6.167

9.  Analogs of alpha-conotoxin MII are selective for alpha6-containing nicotinic acetylcholine receptors.

Authors:  J Michael McIntosh; Layla Azam; Sarah Staheli; Cheryl Dowell; Jon M Lindstrom; Alexander Kuryatov; James E Garrett; Michael J Marks; Paul Whiteaker
Journal:  Mol Pharmacol       Date:  2004-04       Impact factor: 4.436

10.  α4α6β2* nicotinic acetylcholine receptor activation on ventral tegmental area dopamine neurons is sufficient to stimulate a depolarizing conductance and enhance surface AMPA receptor function.

Authors:  Staci E Engle; Pei-Yu Shih; J Michael McIntosh; Ryan M Drenan
Journal:  Mol Pharmacol       Date:  2013-06-20       Impact factor: 4.436

View more
  5 in total

1.  Alpha6-containing nicotinic acetylcholine receptor is a highly sensitive target of alcohol.

Authors:  Fenfei Gao; Dejie Chen; Xiaokuang Ma; Sterling Sudweeks; Jordan T Yorgason; Ming Gao; Dharshaun Turner; Jason Brek Eaton; J Michael McIntosh; Ronald J Lukas; Paul Whiteaker; Yongchang Chang; Scott C Steffensen; Jie Wu
Journal:  Neuropharmacology       Date:  2019-01-30       Impact factor: 5.250

2.  Functional alterations by a subgroup of neonicotinoid pesticides in human dopaminergic neurons.

Authors:  Udo Kraushaar; Marcel Leist; Dominik Loser; Maria G Hinojosa; Jonathan Blum; Jasmin Schaefer; Markus Brüll; Ylva Johansson; Ilinca Suciu; Karin Grillberger; Timm Danker; Clemens Möller; Iain Gardner; Gerhard F Ecker; Susanne H Bennekou; Anna Forsby
Journal:  Arch Toxicol       Date:  2021-03-29       Impact factor: 5.153

3.  Rapid multi-directed cholinergic transmission in the central nervous system.

Authors:  Santhosh Sethuramanujam; Akihiro Matsumoto; Geoff deRosenroll; Benjamin Murphy-Baum; Claudio Grosman; J Michael McIntosh; Miao Jing; Yulong Li; David Berson; Keisuke Yonehara; Gautam B Awatramani
Journal:  Nat Commun       Date:  2021-03-02       Impact factor: 17.694

4.  Levo-tetrahydropalmatine inhibits α4β2 nicotinic receptor response to nicotine in cultured SH-EP1 cells.

Authors:  Yuan-Bing Huang; Ze-Gang Ma; Chao Zheng; Xiao-Kuang K Ma; Devin H Taylor; Ming Gao; Ronald J Lukas; Jie Wu
Journal:  Acta Pharmacol Sin       Date:  2021-07-12       Impact factor: 6.150

5.  Cocaine Directly Inhibits α6-Containing Nicotinic Acetylcholine Receptors in Human SH-EP1 Cells and Mouse VTA DA Neurons.

Authors:  Dejie Chen; Fenfei Gao; Xiaokuang Ma; Jason Brek Eaton; Yuanbing Huang; Ming Gao; Yongchang Chang; Zegang Ma; Taleen Der-Ghazarian; Janet Neisewander; Paul Whiteaker; Jie Wu; Quanxi Su
Journal:  Front Pharmacol       Date:  2019-02-14       Impact factor: 5.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.